Aeterna Zentaris


Maxim Maintains Buy On Aeterna Zentaris Ahead Of Zoptarelin-Dox Data

In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) with a …

Maxim Group Reiterates Buy On Aeterna Zentaris Following Collaboration Agreement With Sinopharm A-Think

In a research report published today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) with a $2.00 price …

UPDATE: MLV Cuts Aeterna Zentaris Price Target; Remains ‘Buyer’ Following Recent Share Declines

In a research report published today, MLV analyst George Zavoico maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) but reduced his price target …

Aeterna Zentaris: The Damage Is Done, Don’t Sell Now, Says Maxim

In a research report released Monday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) but reduced his price target …

H.C. Wainwright Downgrades Aeterna To Neutral Following CRL From FDA

In a research note published today, H.C.

Maxim Raises Aeterna Zentaris Price Target Following 3Q14 Results

In a research report sent to investors today, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Aeterna Zentaris (NASDAQ:AEZS) and raised …

H.C. Wainwright Maintains Buy On Aeterna Zentaris Ahead Of FDA Ruling

In a research report issued today, H.C.

Aeterna Zentaris: Management Is Executing A Productive Turnaround Of The Business, Says Maxim

In a research report issued Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Aeterna Zentaris (AEZS) with a Buy rating and a $5 price target, which represents a …

H.C. Wainwright Reiterates Buy On Aeterna Zentaris; Sees %154 Upside

In a research report released today, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts